Current Report Filing (8-k)
November 30 2016 - 8:51AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 30, 2016
AGENUS INC.
|
(Exact name of registrant as specified in its charter)
|
|
|
|
|
DELAWARE
|
000-29089
|
06-1562417
|
(State or other jurisdiction
|
(Commission
|
(IRS Employer
|
of incorporation)
|
File Number)
|
Identification No.)
|
3 Forbes Road
Lexington, MA
|
02421
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including
area code:
781-674-4400
N/A
(Former name or former address, if changed
since last report.)
|
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01 Other Events.
Agenus Inc. announced today that the first
patient has been dosed in a Phase 1/2 clinical trial of the anti-OX40 agonist antibody INCAGN1949. The trial is being conducted
by, and in collaboration with, Incyte Corporation. The open-label, dose-escalation portion of the trial will evaluate the safety
and tolerability of INCAGN1949 in patients with advanced or metastatic solid tumors and determine its pharmacologically active
and/or maximum tolerated dose. Part 2 of the trial is planned to evaluate the recommended dose of INCAGN1949 in multiple tumor
types.
INCAGN1949 is an agonist antibody targeting
OX40, otherwise known as CD134 or TNFRSF4. OX40 is a co-stimulatory receptor found on activated T cells. OX40 engagement has a
two-pronged effect; it can stimulate proliferation of activated T cells that may promote tumor killing and inhibit the activity
of regulatory T cells that mediate immune suppression. INCAGN1949 was discovered during an earlier collaboration with Ludwig
Cancer Research. This antibody is being co-developed with Incyte Corporation.
The full text of the press release issued
in connection with the announcement is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
|
Description of Exhibit
|
|
|
99.1
|
Press Release dated November 30, 2016.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
Date: November 30, 2016
|
AGENUS INC.
|
|
|
|
|
By:
|
/s/ Christine Klaskin
|
|
|
Christine Klaskin
|
|
|
VP, Finance
|
EXHIBIT INDEX
Exhibit No.
|
Description of Exhibit
|
99.1
|
Press Release dated November 30, 2016.
|
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024